

Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.



FRANKLIN TEMPLETON

Product

Franklin Future of Health and Wellness UCITS ETF

Class SINGLASS • **ISIN** IE0003WEWAX4 • A sub-fund of Franklin Templeton ICAV

Management company (and Manufacturer): Franklin Templeton International Services S.à r.l. ("FTIS"), part of the Franklin Templeton group of companies.

Website: www.franklintempleton.lu

Call (+352) 46 66 67-1 for more information

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising Franklin Templeton International Services S.à r.l. in relation to this Key Information Document.

This PRIIP is authorised in Ireland.

Date of Production of the KID: 30/09/2025

What is this product?

Type

The product is a share class of the Sub-fund Franklin Future of Health and Wellness UCITS ETF (the "Fund") which is part of the Franklin Templeton ICAV (the "Umbrella Fund"), an Irish collective asset-management vehicle constituted as an umbrella fund with segregated liability between Sub-Funds with registration number C167746 and authorised by the Central Bank of Ireland pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011.

Term

The Fund has no maturity date. The Fund could be closed under the conditions laid down in the current prospectus of the Fund.

Objectives

Investment Objective

To provide exposure to companies that are involved in delivering sustainable products and services related to health and wellness globally.

Investment Policy

The Fund invests in equities of developed market companies that utilize technology and demonstrate innovation within the healthcare industry as well as companies that are enabling access to care, health, or wellness provision for a wide range of consumers including the elderly.

To be included in the Index, such securities have, or are expected to have, exposure to the provision of products and/or services that contribute to health and wellbeing.

Such companies operate in industry categories such as senior diseases, genomics, robotic surgery, medical imaging, E-Health and healthcare access, housing and medical care, mind and body wellness and independent aging.

Index Securities are selected from the Solactive GBS Developed Markets All Cap Index (the "Parent Index") based on screening publicly available information such as financial news, business profiles and company publications using the Index Provider's proprietary natural language processing algorithm.

Derivatives and techniques The Fund may use derivatives for hedging and efficient portfolio management.

Strategy The investment manager seeks to minimise the difference between the Fund's performance and that of the benchmark (tracking error), regardless of whether the benchmark level rises or falls.

SFDR category Article 8 (promotes environmental and/or social characteristics under EU regulations).

The benchmark consists of companies with higher environmental, social and governance (ESG) ratings relative to their sector peers. It also excludes or restricts investments in certain industries that are harmful to the environment or society, such as fossil fuels, weapons and tobacco.

For more information see www.franklintempleton.ie/36452

Base currency US dollar (USD).

Benchmark(s) Solactive Sustainable Health and Wellness Index-NR. Used for index tracking only.

The Fund is passively managed and seeks to replicate the benchmark by holding all of the Index securities in a similar proportion to their weighting in the benchmark. Its portfolio, and thus its performance, closely resemble that of the benchmark.

Share Class Policy

For accumulation shares, income from investments is reinvested in the Fund and reflected in the price of shares.

Buying and selling shares

You may buy or sell shares daily through a broker on the stock exchange where the shares are traded. Authorised participants, such as selected financial institutions, may buy or sell shares directly with the fund, on any day the London Stock Exchange is open for business (provided that on such day the markets on which substantially all of the Fund's investments are traded are open).

Intended retail investor

Investors who understand the risks of the Fund and plan to invest for at least 3 to 5 years. The Fund may appeal to investors who:

- are looking for long-term investment growth
- are interested in a thematic exposure to equity markets as part of a diversified portfolio
- have a high risk profile and can tolerate significant short-term changes in the share price

Product availability The Fund is available to all investors with at least basic investment knowledge, through a wide range of distribution channels, with or without the need for advice.

Terms to understand

derivatives: Financial instruments whose value is linked to one or more rates, indexes, share prices or other values.

equities: Securities that represent partial ownership of a company.

efficient portfolio management: A strategy aimed at reducing risk, lowering costs or generating additional capital or income for the Fund through the use of derivatives. These strategies must align with the Funds risk profile.

Depository


The Bank Of New York Mellon SA/NV

Further Information

Please refer to the 'Other relevant information' section below.

What are the risks and what could I get in return?

Risk Indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets.

We have classified this product as 4 out of 7, which is a medium risk class. This rates the potential losses from future performance at a medium level, and poor market conditions could impact the capacity to pay you.

Be aware of currency risk. In some circumstances, you may receive payment in a different currency, so that the final return you get may depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Other risks materially relevant to the product not included in the summary risk indicator:

- Index Related risk
- Secondary Market Trading risk

For a full discussion of all the risks applicable to this Fund, please refer to the "Investment Risk" section of the Fund supplement.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and the suitable benchmark over the last 10 years. Markets could develop very differently in the future.

Recommended holding period: 5 years

Example Investment: 10 000 USD

Scenarios	Returns	If you exit after 1 year	If you exit after 5 years
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.	-	-
Stress	What you might get back after costs	2 170 USD	3 650 USD
Stress	Average return each year	-78.30%	-18.26%
Unfavourable	What you might get back after costs	8 910 USD	9 660 USD
Unfavourable	Average return each year	-10.90%	-0.69%
Moderate	What you might get back after costs	10 830 USD	16 060 USD
Moderate	Average return each year	8.30%	9.94%
Favourable	What you might get back after costs	12 940 USD	20 780 USD
Favourable	Average return each year	29.40%	15.75%

The stress scenario shows what you might get back in extreme market circumstances.

Unfavourable scenario: This type of scenario occurred for an investment using the benchmark as stated in the prospectus between April 2022 and December 2024.

Moderate scenario: This type of scenario occurred for an investment using the benchmark as stated in the prospectus between October 2017 and October 2022.

Favourable scenario: This type of scenario occurred for an investment using the benchmark as stated in the prospectus between December 2016 and December 2021.

What happens if Franklin Templeton International Services S.à r.l. is unable to pay out?

Franklin Templeton International Services S.à r.l. ("FTIS") is the management company of the Fund, but the assets are held separately from FTIS by the depositary. The Bank Of New York Mellon SA/NV, Dublin Branch, The Shipping Office, Sir John Rogerson's Quay, Dublin 2, Ireland, as the appointed depositary of the Fund, is liable to the Fund or its shareholders for any loss of financial instruments held in custody by it or its delegates (cash could however be lost in case of default of the depositary or its delegates).

There is no compensation or guarantee scheme protecting you from a default of the Fund's depositary.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario
- USD 10 000 is invested

Costs over Time	If you exit after 1 year	If you exit after 5 years
Total costs	39 USD	290 USD
Annual cost impact (*)	0.4%	0.4% each year

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 10.3% before costs and 9.9% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

Please note that the figures shown here do not include any additional fees that may be charged by your distributor, advisor or any insurance wrapper in which the fund may be placed.

Composition of Costs

One-off costs upon entry or exit	Description	If you exit after 1 year
Entry costs	We do not charge an entry fee.	0 USD
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	0 USD
Ongoing costs taken each year	Description	If you exit after 1 year
Management fees and other administrative or operating costs	0.30% of the value of your investment per year. This is an estimate based on actual costs over the last year.	30 USD
Transaction costs	0.09% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	9 USD
Incidental costs taken under specific conditions	Description	If you exit after 1 year
Performance fees (and carried interest)	There is no performance fee for this product.	0 USD

How long should I hold it and can I take money out early?

Recommended holding period: 5 year(s)

This Fund has no minimum required holding period. We consider that the 5 year recommended holding period is appropriate because the Fund is designed for long-term investment. You may sell your shares on any dealing day. The value of your investments may go down as well as up irrespective of the period you are holding your investments, depending on such factors as the performance of the Fund, movements in stock and bond prices, and conditions in financial markets generally. Please contact your broker, financial adviser or distributor for information on any costs and charges relating to the sale of the shares.

How can I complain?

Investors who would like to receive the procedures relating to complaints handling or wish to make a complaint about the Fund, the operation of FTIS or the person advising on or selling the Fund, should go on the website www.franklintempleton.lu, contact Franklin Templeton International Services, S.à r.l., 8A, rue Albert Borschette L-1246 Luxembourg, or send an e-mail to the client service department at etfteamta@statestreet.com & kure_transaction_monitoring_client_communication@statestreet.com.

Other relevant information

For further information on the investment objective and policies of the Fund, please refer to the Fund supplement within the current prospectus. Copies of the latest prospectus, including the Fund's supplement, and the latest annual & semi-annual reports of Franklin Templeton ICAV, as well as the latest prices of shares and other information on the Fund (including other share classes of the Fund) are available in English and, selectively, in certain other languages on the website www.franklintempleton.ie, your local Franklin Templeton website, or may be obtained free of charge from the Administrator: BNY Mellon Fund Services (Ireland) DAC, The Shipping Office, Sir John Rogerson's Quay, Dublin 2, Ireland or your financial adviser.

The past performance presenting on the last 1 year and previous performance scenario calculations are available under:

- https://docs.data2report.lu/documents/FTI/KID_PP/KID_annex_PP_IE0003WEWAX4_en.pdf

- https://docs.data2report.lu/documents/FTI/KID_PS/KID_annex_PS_IE0003WEWAX4_en.pdf

The Paying Agent of Franklin Templeton ICAV in Switzerland is BNP PARIBAS, Paris, Zurich branch, Selnaustrasse 16, CH-8002 Zurich.

The representative of Franklin Templeton ICAV in Switzerland is Franklin Templeton Switzerland Ltd., Stockerstrasse 38, 8002 Zurich.

The relevant documents such as the prospectus and the Key Information Document, the articles of association and the annual and semi-annual report can be obtained free of charge from the representative in Switzerland, Franklin Templeton Switzerland Ltd., Stockerstrasse 38, 8002 Zürich (Tel. + 41 44 217 81 81), and on www.franklintempleton.ch and www.fundinfo.com.